- TheStreet.com•18 hours ago
Spark believes temporary treatment with steroids can arrest the immune response before it causes factor IX levels to fall to a point where bleeding risk becomes a problem.
- Business Wire•18 hours agoNew Phase 2 Results Show Investigational Compound Glasdegib Improved Overall Survival in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
Today, Pfizer Inc. announced new data from a randomized Phase 2 study of glasdegib , an oral, smoothened inhibitor, showing the addition of glasdegib to low-dose cytarabine significantly increased overall survival when compared to LDAC alone in patients with acute myeloid leukemia or high-risk myelodysplastic syndrome who were ineligible for intensive chemotherapy .
- GlobeNewswire•20 hours agoSpark Therapeutics and Pfizer Present Updated Preliminary Data from Hemophilia B Phase 1/2 Trial Suggesting Consistent and Sustained Levels of Factor IX Activity at Annual ASH Meeting
Together, all nine participants have reduced infusions of factor IX concentrates by 99 percent over cumulative 1,650 days. Seven infused participants who have progressed to at least 12 weeks post-vector ...
PFE.BA : Summary for PFIZER INC CEDEAR EACH 2 REP 1 - Yahoo Finance
Pfizer Inc. (PFE.BA)
Buenos Aires - Buenos Aires Delayed Price. Currency in ARS
Add to watchlist
|Day's Range||252.30 - 252.30|
|52 Week Range||212.20 - 285.00|
|PE Ratio (TTM)||253.31|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|